Tissue Regenix Group PLC's (LON:TRX) CEO Danny Lee and CFO David Cocke about their final results for the year which ended 31 December 2020. The firm is now confident in its prospects once the COVID-19 pandemic has subsided and healthcare procedures return to a normalised level.
The represent their move from an R&D organisation to now focus on commercialisation, there have been a few changes to the board which Lee talks through and explains their new strategy as a company.
Highlights include, entering the UK and specific EU markets with OrthoPure XT and established white label manufacturing capabilities with a large global partner.